Mocetinostat for relapsed classical Hodgkin's lymphoma: An open-label, single-arm, phase 2 trial

The Lancet Oncology

Volumn 12, Issue 13, 2011, Pages 1222-1228

  Younes, Anas ^a   Oki, Yasuhiro ^a   Bociek, R Gregory ^b   Kuruvilla, John ^c   Fanale, Michelle ^a   Neelapu, Sattva ^a   Copeland, Amanda ^a   Buglio, Daniela ^a   Galal, Ahmed ^d   Besterman, Jeffrey ^e   Li, Zuomei ^e   Drouin, Michel ^e   Patterson, Tracy ^e   Ward, M Renee ^f   Paulus, Jessica K ^g   Ji, Yuan ^a   Medeiros, L Jeffrey ^a   Martell, Robert E ^g  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d ROYAL VICTORIA HOSPITAL   (Canada)

^e METHYLGENE INC   (Canada)

^f CELGENE CORPORATION   (United States)

^g TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; BLEOMYCIN; DNA TOPOISOMERASE; MICROTUBULE AGENT; MOCETINOSTAT; PLATINUM; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLASSICAL HODGKIN LYMPHOMA; CLINICAL ASSESSMENT; CONTROLLED STUDY; COUGHING; DEHYDRATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HEART ATRIUM FIBRILLATION; HUMAN; HYPOTENSION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PERICARDIAL EFFUSION; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; ST SEGMENT ELEVATION; SYNCOPE; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZAMIDES; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HISTONE DEACETYLASE INHIBITORS; HODGKIN DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NORTH AMERICA; PYRIMIDINES; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 82555187781     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70265-0     Document Type: Article

References (35)

1. Marshall NA, Christie LE, Munro LR, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004, 103:1755-1762.
2. Ishida T, Ishii T, Inagaki A, et al. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 2006, 66:5716-5722.
3. Poppema S Immunobiology and pathophysiology of Hodgkin lymphomas. Hematology Am Soc Hematol Educ Program 2005, 231-238.
4. Connors JM Clinical challenges in Hodgkin lymphoma: an historical perspective. Hematology Am Soc Hematol Educ Program 2008, 320.
5. Eichenauer DA, Fuchs M, Borchmann P, Engert A Hodgkin's lymphoma: current treatment strategies and novel approaches. Expert Rev Hematol 2008, 1:63-73.
6. Kuruvilla J, Keating A, Crump M How I treat relapsed and refractory Hodgkin lymphoma. Blood 2011, 117:4208-4217.
7. Cashen AF, Bartlett NL Salvage regimens for Hodgkin lymphoma. Clin Adv Hematol Oncol 2008, 6:517-524.
8. Younes A Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2009, 507-519.
9. Horning S, Fanale M, deVos S, et al. Defining a population of Hodgkin lymphoma patients for novel therapeutics: an international effort. Ann Oncol 2008, 19(suppl 4). abstr 118.
10. Marks PA, Xu WS Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 2009, 107:600-608.
11. Lane AA, Chabner BA Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009, 27:5459-5468.
12. Faretta M, Di Croce L, Pelicci PG Effects of the acute myeloid leukemia-associated fusion proteins on nuclear architecture. Semin Hematol 2001, 38:42-53.
13. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH, Evans RM Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998, 391:811-814.
14. Prince HM, Bishton MJ, Harrison SJ Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 2009, 15:3958-3969.
15. Younes A Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nat Rev Clin Oncol 2011, 8:85-96.
16. Lemoine M, Younes A Histone deacetylase inhibitors in the treatment of lymphoma. Discov Med 2010, 10:462-470.
17. Zhou N, Moradei O, Raeppel S, et al. Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor. J Med Chem 2008, 51:4072-4075.
18. Fournel M, Bonfils C, Hou Y, et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 2008, 7:759-768.
19. Buglio D, Khaskhely NM, Voo KS, Martinez-Valdez H, Liu YJ, Younes A HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma. Blood 2011, 117:2910-2917.
20. Buglio D, Georgakis GV, Hanabuchi S, et al. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 2008, 112:1424-1433.
21. Buglio D, Mamidipudi V, Khaskhely NM, et al. The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism. Br J Haematol 2010, 151:387-396.
22. Younes A, Ong T-C, Ribrag V, et al. Efficacy of panobinostat in phase II study in patients with relapsed/refractory Hodgkin lymphoma (HL) after high-dose chemotherapy with autologous stem cell transplant. Blood 2009, 114. abstr 923.
23. Younes A, Pro B, Fanale M, et al. Isotype-selective HDAC inhibitor MGCD0103 decreases serum TARC concentrations and produces clinical responses in heavily pretreated patients with relapsed classical Hodgkin lymphoma (HL). Blood 2007, 110. abstr 2566.
24. Buglio D, Younes A Histone deacetylase inhibitors in Hodgkin lymphoma. Invest New Drugs 2010, 28(suppl 1):S21-S27.
25. Blum KA, Advani A, Fernandez L, et al. Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br J Haematol 2009, 147:507-514.
26. Siu LL, Pili R, Duran I, et al. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol 2008, 26:1940-1947.
27. Garcia-Manero G, Assouline S, Cortes J, et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008, 112:981-989.
28. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586.
29. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, version 3.0. NIH (accessed Jan 31, 2011). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_30.
30. Simon R Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10.
31. Buglio D, Georgiakis GV, Hanabuchi S, et al. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 2008, 112:1424-1433.
32. Kirschbaum MH, Goldman BH, Zain JM, et al. Vorinostat (suberoylanilide hydroxamic acid) in relapsed or refractory Hodgkin lymphoma: SWOG 0517. Blood 2007, 110. abstr 2574.
33. Sureda A, Younes A, Ben-Yehuda D, et al. Final analysis: phase II study of oral panobinostat in relapsed/refractory Hodgkin lymphoma patients following autologous hematopoietic stem cell transplant. Blood 2010, 116. abstr 419.
34. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010, 363:1812-1821.
35. Younes A, Hagenbeek A, Coiffier B Optimising the lymphoma response criteria in the era of targeted therapy. Lancet Oncol 2011, 12:616-617.